search
Back to results

A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain

Primary Purpose

Interstitial Cystitis

Status
Recruiting
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Multimodal Bundle Drugs
Operative Cystoscopy
Behavioral health consultation/therapy
Pelvic floor physical therapy
Usual Urogynecologic care
Bladder Instillation
Vaginal estrogen
Methenamine
Amitriptyline/Gabapentin
Sponsored by
Jocelyn Fitzgerald
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Interstitial Cystitis

Eligibility Criteria

18 Years - 99 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria: Female patient 18 years of age or older diagnosis of Interstitial Cystitis/Painful Bladder Syndrome, scoring 6 points or higher on O'Leary Sant Questionnaire Exclusion Criteria: Active pelvic or bladder infection within past 2 weeks contraindications to medications or intervention therapeutics inability to speak or read English pelvic floor interventional procedure including bladder instillations 4 weeks prior to study recruitment meets criteria for diagnostic laparoscopy internal referral (to reduce severity bias) Note: patients are not excluded for currently taking any medication on the treatment list. Patients can be treated for UTI during the study period.

Sites / Locations

  • Magee Womens HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Multimodal care bundle

Usual care

Arm Description

Components of multimodal care bundle MD Evaluation On site pelvic floor physical therapy Behavioral health consult with appropriate psychiatric referrals/treatments Central sensitization/neurogenic pain: Amitriptyline 10-50mg Or Gabapentin (doses range from 100mg po tid to 600mg po tid) Urinary symptoms IC/PBS: Spasm: Overactive bladder medication chosen based on patient characteristics/insurance, dose may be increased as tolerated (Oxybutynin/Trospium/Detrol vs. Mirabegron) Microbiome: Methenamine Vaginal estrogen At least once within 12 weeks of initial visit: Operative cystoscopy Bladder instillations x 6 weeks (lidocaine, heparin, sodium bicarb, Kenalog, gentamicin) Pudendal/Levator and/or Obturator internus nerve block (120mg Kenalog and 0.25% Marcaine, total 23cc)

IC/PBS treatments as directed by Urogynecology specialist

Outcomes

Primary Outcome Measures

--O'Leary Sant Questionnaire (OLS), comprised of Interstitial Cystitis Symptom Index (ICSI) and Problem Index (ICPI), at 12 weeks from baseline MCID: 4 points for ICSI Change in O'Leary Sant Questionnaire Scores >4 points
Validated Questionnaire for evaluating Interstitial Cystitis. Scale range ICSI 0-20, ICPI 0-16, total 0-36. Higher score=worse pain. Improvement of 1-2 point is consider clinically significant.

Secondary Outcome Measures

Healthcare encounters
Number of encounters with the UPMC healthcare system

Full Information

First Posted
November 23, 2022
Last Updated
December 16, 2022
Sponsor
Jocelyn Fitzgerald
search

1. Study Identification

Unique Protocol Identification Number
NCT05658874
Brief Title
A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain
Official Title
A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
December 1, 2022 (Actual)
Primary Completion Date
December 1, 2023 (Anticipated)
Study Completion Date
January 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Jocelyn Fitzgerald

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The goal of this clinical trial is to compare two different treatment patterns in patients with chronic bladder pain. The main questions the investigators are seeking to answer is if bladder pain improves before and after treatment using a painful bladder scale. The participant will have 5 visits to evaluate your symptoms with questionnaires, at least one procedural visit, and must participate in physical therapy and some kind of behavioral health therapy. This study will assess participant response to a bundled-care approach to chronic bladder pain both pre-and post intervention as well as compared to a group of participants receiving typical care.
Detailed Description
Objectives: The goals of this research program are to evaluate the patient-reported outcomes of a multimodal care bundle for patients presenting to a multidisciplinary chronic pelvic pain clinic compared to "usual care" in an Urogynecology clinic. Primary Aim: To compare pre and post intervention self-evaluation of pain and function scores in women with chronic pain syndromes with a primary finding of urinary/bladder pain symptoms with or without levator spasm who undergo multi-disciplinary, bundled care compared with usual care in a Urogynecology clinic setting. Secondary Aims: a) To identify and phenotype "non-responders" to a bundled approach to Interstitial Cystitis/Painful Bladder Syndrome/Chronic Pelvic Pain (IC/PBS/CPP). Hypothesis: We hypothesize that a bundled, multidisciplinary care approach will significantly improve patient scores on validated outcomes questionnaires compared to usual care. Methods: All treatment plans, medications, and procedures recommended for patients involved in this study are within the current standards of care for IC/PBS/CPP, regardless of treatment arm and are known to be safe interventions. Study Design: Single center, randomized pre-post intervention/prospective cohort study32 of usual FPMRS care vs. multimodal, multidisciplinary care bundle (MMCB). Setting: Patients will be recruited from an outpatient Urogynecology clinic. They will subsequently be randomized to a Multidisciplinary chronic pelvic pain clinic at an alternate site vs. continuing usual outpatient care in Urogynecology as above.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Interstitial Cystitis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Single center, randomized pre-post intervention/prospective cohort study of usual Urogynecology care vs. multimodal, multidisciplinary care bundle (MMCB).
Masking
None (Open Label)
Allocation
Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Multimodal care bundle
Arm Type
Experimental
Arm Description
Components of multimodal care bundle MD Evaluation On site pelvic floor physical therapy Behavioral health consult with appropriate psychiatric referrals/treatments Central sensitization/neurogenic pain: Amitriptyline 10-50mg Or Gabapentin (doses range from 100mg po tid to 600mg po tid) Urinary symptoms IC/PBS: Spasm: Overactive bladder medication chosen based on patient characteristics/insurance, dose may be increased as tolerated (Oxybutynin/Trospium/Detrol vs. Mirabegron) Microbiome: Methenamine Vaginal estrogen At least once within 12 weeks of initial visit: Operative cystoscopy Bladder instillations x 6 weeks (lidocaine, heparin, sodium bicarb, Kenalog, gentamicin) Pudendal/Levator and/or Obturator internus nerve block (120mg Kenalog and 0.25% Marcaine, total 23cc)
Arm Title
Usual care
Arm Type
Active Comparator
Arm Description
IC/PBS treatments as directed by Urogynecology specialist
Intervention Type
Drug
Intervention Name(s)
Multimodal Bundle Drugs
Other Intervention Name(s)
Overactive Bladder Medication( Trospium/Oxybutynin/Detrol vs. Mirabegron)
Intervention Description
multimodal pain therapy
Intervention Type
Procedure
Intervention Name(s)
Operative Cystoscopy
Intervention Description
Evaluate bladder and treat Hunner lesions with kenalog or fulguration as appropriate
Intervention Type
Behavioral
Intervention Name(s)
Behavioral health consultation/therapy
Intervention Description
Patient to see behavioral health/psychiatric care
Intervention Type
Other
Intervention Name(s)
Pelvic floor physical therapy
Intervention Description
Patient to have evaluation and treatment by a trained pelvic floor physical therapist
Intervention Type
Other
Intervention Name(s)
Usual Urogynecologic care
Intervention Description
Usual care from practicing academic Urogynecologist
Intervention Type
Drug
Intervention Name(s)
Bladder Instillation
Intervention Description
Intravesical lidocaine, heparin, sodium bicarb, Kenalog, gentamicin
Intervention Type
Drug
Intervention Name(s)
Vaginal estrogen
Intervention Description
Topical vaginal estradiol application
Intervention Type
Drug
Intervention Name(s)
Methenamine
Intervention Description
UTI prevention/bladder therapeutic
Intervention Type
Drug
Intervention Name(s)
Amitriptyline/Gabapentin
Intervention Description
Part of multimodal pain therapy
Primary Outcome Measure Information:
Title
--O'Leary Sant Questionnaire (OLS), comprised of Interstitial Cystitis Symptom Index (ICSI) and Problem Index (ICPI), at 12 weeks from baseline MCID: 4 points for ICSI Change in O'Leary Sant Questionnaire Scores >4 points
Description
Validated Questionnaire for evaluating Interstitial Cystitis. Scale range ICSI 0-20, ICPI 0-16, total 0-36. Higher score=worse pain. Improvement of 1-2 point is consider clinically significant.
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Healthcare encounters
Description
Number of encounters with the UPMC healthcare system
Time Frame
1 year

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Female patient 18 years of age or older diagnosis of Interstitial Cystitis/Painful Bladder Syndrome, scoring 6 points or higher on O'Leary Sant Questionnaire Exclusion Criteria: Active pelvic or bladder infection within past 2 weeks contraindications to medications or intervention therapeutics inability to speak or read English pelvic floor interventional procedure including bladder instillations 4 weeks prior to study recruitment meets criteria for diagnostic laparoscopy internal referral (to reduce severity bias) Note: patients are not excluded for currently taking any medication on the treatment list. Patients can be treated for UTI during the study period.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Judy Gruss, RN
Phone
4126415388
Email
grussja@upmc.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jocelyn J Fitzgerald, MD
Organizational Affiliation
University of Pittsburgh
Official's Role
Principal Investigator
Facility Information:
Facility Name
Magee Womens Hospital
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jocelyn J Fitzgerald, MD
Email
fitzgeraldjj2@upmc.edu

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain

We'll reach out to this number within 24 hrs